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Purpose: Colistin resistance in Acinetobacter baumannii (A. baumannii) is mediat-
ed by a complete loss of lipopolysaccharide production via mutations in lpxA, lpxC, 
and lpxD gene or lipid A modifications via mutations in the pmrA and pmrB genes. 
However, the exact mechanism of therapy-induced colistin resistance in A. bau-
mannii is not well understood. Materials and Methods: We investigated the geno-
typic and phenotypic changes that underlie pan-drug resistance mechanisms by de-
termining differences between the alterations in extensively drug-resistant (XDR) 
A. baumannii (AB001 and AB002) isolates and a pan-drug resistant (PDR) counter-
part (AB003) recovered from one patient before and after antibiotic treatment, re-
spectively. Results: All three clinical isolates shared an identical sequence type 
(ST138), belonging to the global epidemic clone, clonal complex 92, and all pro-
duced OXA-23 carbapenemase. The PDR AB003 showed two genetic differences, 
acquisition of armA gene and an amino acid substitution (Glu229Asp) in pmrB gene, 
relative to XDR isolates. No mutations were detected in the pmrA, pmrC, lpxA, lpxC, 
or lpxD genes in all three isolates. In matrix-assisted laser desorption ionization-time 
of flight analysis, the three isolates commonly showed two major peaks at 1728 m/z 
and 1912 m/z, but peaks at 2034 m/z, 2157 m/z, 2261 m/z, and 2384 m/z were de-
tected only in the PDR A. baumannii AB003 isolate. Conclusion: Our results show 
that changes in lipid A structure via a mutation in the pmrB gene and acquisition of 
armA gene might confer resistance to colistin and aminoglycosides to XDR A. bau-
mannii strains, resulting in appearance of a PDR A. baumannii strain of ST138.
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INTRODUCTION
The extensive use of antimicrobial agents and the propensity of pathogenic bacteria 
that accumulate antimicrobial resistance have led to a considerable increase in 
pathogenic bacteria acquiring resistance to multiple categories of antimicrobial 
agents. As this problem continues to grow, the definition of terms such as multi-
drug resistant (MDR), extensively drug-resistant (XDR), and pan-drug resistant 
(PDR) strains were standardized in order to more specifically define those microor-
ganisms. MDR strains are defined as non-susceptible to at least one agent in three 
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baumannii isolate (AB001) was first recovered from a respi-
ratory tract specimen on day five, and it was then serially re-
covered from respiratory tract specimens. And an XDR A. 
baumannii isolate (AB002) was recovered from a urinary 
specimen on day six. Intravenous administration of colisti-
methate sodium (150 mg/day) was started on day six. After 
five days of colistin therapy, a colistin-resistant A. bauman-
nii isolate (AB003) was recovered from a blood specimen, 
which prompted the physicians to change antibiotics to tige-
cycline. However, urinary tract infection, acute renal failure, 
atelectasis at both lungs, and sepsis were not controlled. On 
day 17, the patient was transferred to a local hospital near the 
patient’s home for continuation of treatment. In this study, 
we included the two colistin-susceptible XDR A. baumannii 
isolates (AB001 and AB002), which were recovered from 
the respiratory tract and urinary specimens, respectively, and 
their colistin-resistant counterpart (AB003). The isolates 
were identified as A. baumannii using the Vitek GNI system 
(bioMérieux, Marcy l’Etoile, France) and sequence analysis 
of the RNA polymerase β-subunit (rpoB) gene.14 A. bauman-
nii ATCC 19606 was used as the reference strain.
Antimicrobial susceptibility testing
Antimicrobial susceptibilities were determined using antibi-
otic-containing disks (Becton Dickinson, Sparks, MD, 
USA) on Mueller-Hinton agar (Difco Laboratories, Detroit, 
MI, USA). The minimum inhibitory concentrations (MICs) 
of meropenem and imipenem were determined using the 
agar dilution method, and the MIC of colistin was deter-
mined by the E-test (bioMérieux) according to the Clinical 
and Laboratory Standards Institute guidelines.15
Multi-locus sequence typing (MLST)
PCR and sequencing experiments were performed on seven 
housekeeping genes encoding citrate synthase (gltA), DNA 
gyrase subunit B (gyrB), glucose dehydrogenase B (gdhB), 
homologous recombination factor (recA), 60-kDa chapero-
nin (cpn60), glucose-6-phosphate isomerase (gpi), and RNA 
polymerase sigma factor (rpoD), as described previously.6,16 
Nucleotide sequences of both strands were determined. Al-
lelic profiles of the seven housekeeping genes and STs of 
the strains were analyzed using the Acinetobacter MLST da-
tabase (http://www.pasteur.fr/recherche/genopole/PF8/ mlst/).
Pulsed-field gel electrophoresis (PFGE) 
Pulsed-field gel electrophoresis (PFGE) was performed with 
SmaI-digested genomic DNA extracted from the three iso-
or more antimicrobial categories, XDR strains are defined as 
non-susceptible to at least one agent in all but two or fewer 
antimicrobial categories, and PDR strains are defined as 
non-susceptible to all agents in all antimicrobial categories.1
Acinetobacter baumannii (A. baumannii) is associated 
with infections including bacteremia, pneumonia, meningi-
tis, and urinary tract infections especially in patients hospi-
talized in intensive care units (ICUs).2,3 The prevalence of 
XDR A. baumannii isolates with carbapenem resistance has 
persistently increased, and most of XDR A. baumannii iso-
lates in Asia belong to the globally-distributed clone, clonal 
complex 92.4-7 After the reintroduction of colistin in clinical 
practice to treat infections caused by XDR A. baumannii 
due to the lack of applicable antibiotics, the emergence of 
PDR A. baumannii strains with colistin resistance has repeat-
edly been reported in many parts of the world.8-11
According to a few in vitro studies regarding colistin re-
sistance mechanisms in A. baumannii, colistin resistance is 
mediated by a complete loss of lipopolysaccharide (LPS) 
production via mutations in LPS producing genes (lpxA, 
lpxC, and lpxD) or by mutations in the pmrA and pmrB genes 
that encode a two-component signal transduction system.12,13 
However, the exact mechanism of therapy-induced colistin 
resistance in A. baumannii is not well understood.
Here, we studied colistin resistance mechanisms by evalu-
ating the genetic alterations between two colistin-susceptible 
XDR A. baumannii clinical isolates and a colistin-resistant 
counterpart isolated from one patient before and after colis-
tin therapy, respectively. Furthermore, we investigated the 
genetic determinants of antimicrobial resistance to various 
antibiotics and the molecular epidemiology of the clinical 
isolates.
MATERIALS AND METhODS
Patient characteristics and bacterial strains
A 72-year-old man with a history of hypertension, atrial fi-
brillation, and diabetes mellitus was admitted to the emer-
gency department of a tertiary-care hospital in Seoul, Korea, 
on August 29th, 2011 due to abdominal pain. Abdominal 
computed tomography revealed an impending thoracoab-
dominal aortic aneurysm, and a graft replacement of the ab-
dominal aorta was performed. After emergency surgery, he 
was admitted to the ICU and was mechanically ventilated 
from day one. He was treated with ciprofloxacin (400 mg/
day) and piperacillin+tazobactam (6.75 g/day). An XDR A. 
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and sequencing.13,23 Briefly, genomic DNA was extracted 
using a QIAamp DNA extraction kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s protocol. After PCR, 
amplicons were purified using a QIAquick Gel Extraction 
Kit (Qiagen) and sequenced using an ABI 3500dx system 
(Applied Biosystems, Foster City, CA, USA). Sequences for 
all antimicrobial resistance determinant loci in A. baumannii 
isolates were compared using the GenBank database (http://
www.ncbi.nlm.nih.gov) with reference sequences of A. bau-
mannii ATCC 17978 (GenBank accession number CP000 521).
Analysis of lipid A structure
LPS and lipid A were extracted from whole bacterial cells 
using Tri-Reagent extraction and mild acid hydrolysis meth-
ods, and were then subjected to negative-ion matrix-assisted 
laser desorption ionization-time of flight (MALDI-TOF) 
mass spectrometer (Bruker Daltonik GmbH, Leipzig, Ger-
many) analysis in the negative reflective mode.24
RESULTS
Antimicrobial susceptibilities and antimicrobial 
resistance determinants
The antimicrobial resistance determinants of the two colis-
tin-susceptible XDR A. baumannii isolates (AB001 and 
lates using a CHEF-DRII device (Bio-Rad, Hercules, CA, 
USA). The conditions of PFGE were 6 V/cm for 20 h with 
pulse times of 3‒10 seconds at a temperature of 11ºC. SmaI-
digested band patterns were analyzed using Molecular Ana-
lyst Fingerprinting Software Ver. 3.2 (Bio-Rad). The PFGE 
patterns were interpreted using the criteria of Tenover, et al.17
Characterization of antimicrobial resistance 
determinants 
PCR and sequence analysis of antimicrobial resistance de-
terminants including blaOXA51-like, blaOXA-23, blaAmpC, gyrA, 
parC, and armA genes were performed according to meth-
ods described in previous studies.18-21 The presence of IS 
Aba1 upstream of the blaOXA51-like, blaOXA-23, and blaAmpC 
genes was also evaluated.22 LPS-producing genes (lpxA, 
lpxC, and lpxD) and pmrA and pmrB genes encoding a two-
component signal transduction system were sought by PCR 
Table 1. Characteristics of A. baumannii Clinical Isolates Included in This Study
Isolate*
Antimicrobial susceptibilities (inhibition zone diameter, mm) MIC (mg/mL) MLST
CAZ CTX FEP AN GM CIP CL MEM IPM ST
AB001 R (9) R (9) R (10) S (24) S (18) R (9) 0.25 256 64 138
AB002 R (9) R (9) R (10) S (23) S (17) R (9) 0.25 256 64 138
AB003 R (9) R (9) R (11) R (9) R (9) R (9) 16 256 64 138
AN, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CL, colistin; CTX, cefotaxime; FEP, cefepime; GM, gentamicin; IPM, imipenem; MEM, meropenem; 
MLST, multi-locus sequence typing; R, resistance; S, susceptible; ST, sequence type.
*AB001 and AB002 are colistin-susceptible isolates and AB003 is the colistin-resistant counterpart.
Table 2. Antibiotic Resistance Genes of Acinetobacter baumannii Clinical Isolates
Strain†
Detected antimicrobial resistance determinants Detected mutations
blaOXA-51-
like*
ISAba1-
blaOXA-23
ISAba1-
blaAmpC
armA gyrA parC pmrB pmrA and C lpxA, C, and D
AB001 + +  + ND Ser83Leu Ser80Leu WT WT WT
AB002 + + +  ND Ser83Leu Ser80Leu WT WT WT
AB003 + + +  + Ser83Leu Ser80Leu
Glu229Asp 
 (A→T substitution 
at nt687)
WT WT
ND, not detected; WT, wild type.
*ISAba1 upstream of blaOXA-51-like was not detected in all isolates.
†Genes detected by PCR and sequencing.
Fig. 1. SmaI-macrorestiction patterns of two colistin-susceptible isolates 
(AB001 and AB002) and a colistin-resistant isolate (AB003). All three iso-
lates showed 100% of similarity.
AB001
AB002
AB003
Identity (%) 100
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ceftazidime and cefepime, and they carried and the ISAba1-
blaAmpC structure. MICs of imipenem and meropenem for all 
three isolates were greater than 32 mg/L, and they carried 
the blaOXA-23 gene with an insertion sequence ISAba1 up-
stream of the gene. The MIC of colistin for both AB001 and 
AB002 isolates was 0.25 mg/L, while that for AB003 isolate 
was 16 mg/L (Table 1 and 2).
AB002) and a PDR A. baumannii isolate (AB003) were 
evaluated. All three isolates showed resistance to ciprofloxa-
cin, and they contained the gyrA gene with an amino acid 
substitution (Ser83Leu). While isolates AB001 and AB002 
showed susceptibility to amikacin and gentamicin, the AB003 
isolate showed resistance to these aminoglycosides and har-
bored the armA gene. All three isolates showed resistance to 
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Fig. 2. Mass spectrometry of lipid A extracted from the colistin-susceptible isolates (A) AB001 and (B) AB002 and their colistin-resistant counterpart (C) 
AB003 with Glu229Asp in pmrB gene. In MALDI-TOF analysis, AB001, AB002, and AB003 isolates all showed two major peaks at 1728 m/z and 1912 m/z, but 
peaks at 2034 m/z, 2157 m/z, 2261 m/z, and 2384 m/z were detected only in the PDR A. baumannii AB003 isolate. MALDI-TOF, matrix-assisted laser desorption 
ionization-time of flight; PDR, pan-drug resistant.
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AB003 harbored Glu229Asp mutation in the pmrB gene, 
while the isolate carried wild-type LPS-producing genes 
(lpxA, lpxC, and lpxD). The mutant pmrAB genes are in-
volved in LPS modification by adding 4-amino-4-deoxy-L-
arabinose (Ara4N) and/or phosphoethanolamine (pEtN) to 
lipid A.23,28,29 In MALDI-TOF analysis, we observed the ex-
pected spectra ion peaks of 1728 m/z and 1912 m/z in all 
three isolates, AB001, AB002, and AB003. However, the 
peaks of 2034 m/z, 2157 m/z, 2261 m/z, and 2384 m/z were 
detected only in the AB003 strain, which contained the 
pmrB mutation. Possibly, these peaks were generated by the 
addition of one or two pEtN (123 m/z) residues to bis-phos-
phorylated hepta- and octa-acylated lipid A molecules. 
These modifications should affect the electrostatic interac-
tion of certain cationic antimicrobial-peptide resistance de-
terminants with the bacterial cell surface, and act as one of 
the colistin-resistant mechanisms.30,31
In our study, the AB003 acquired a mutation in the pmrB 
gene after five days of colistin therapy. It should be a short 
period of time to obtain a resistance, but colistin resistant A. 
baumannii were collected from patients who received colis-
tin therapy for 7‒19 days.26,32
The AB003 strain also harbored the armA gene and showed 
resistance to amikacin (<9 mm of disk diffusion test). After 
admission, the patient did not received aminoglycoside 
agents, such as tobramycin and amikacin. Therefore, it is 
highly likely that the armA is located on plasmids was inci-
dentally transferred from another A. baumannii clone.18,33
In our study, all three isolates showed identical SmaI-mac-
rorestriction patterns by PFGE and identified as an identical 
ST, ST 138 (1-3-3-2-2-50-3), indicating that they are a 
clone. All three isolates shared the gyrA gene with a same 
mutation, and they carried identical resistance genes IS 
Aba1-blaAmpC and ISAba1-blaOXA-23. However, AB003 car-
ried only the pmrB gene with a mutation of Glu229Asp and 
the armA gene. Therefore, AB003 might acquire resistance 
to colistin and aminoglycosides by in vivo selection during 
colistin treatment from the XDR parental strains (AB001 
and AB002).
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Strain type
All three isolates were identified as an identical ST, ST 138 
(1-3-3-2-2-50-3), and they showed identical SmaI-macror-
estriction patterns by PFGE (Fig. 1).
Molecular analysis of the colistin-susceptible/resistant 
isogenic clinical isolates
The sequences of the pmrB gene in the two colistin-suscep-
tible AB001 and AB002 isolates were identical to those of 
the reference A. baumannii ATCC 17978, whereas the PDR 
A. baumannii AB003 isolate harbored a novel mutation (en-
coding a Glu229Asp change) in the pmrB gene (Table 2). 
No mutations were detected in the pmrA, pmrC, lpxA, lpxC, 
and lpxD genes in all three isolates.
Analysis of lipid A structure
The two colistin-susceptible AB001 and AB002 isolates and 
the PDR A. baumannii AB003 isolate all showed two major 
peaks at 1729 m/z and 1911 m/z in negative-ion MALDI-
TOF mass spectra. These two major peaks most likely cor-
respond to bis-phosphorylated hexa- and hepta-acylated lip-
id A, respectively. Spectra for the lipid A structure from the 
PDR A. baumannii AB003 isolate were distinct from those 
of AB001 and AB002, as it showed additional peaks at 2034 
m/z, 2157 m/z, 2261 m/z, and 2384 m/z (Fig. 2).
DISCUSSION
The extensive use of antimicrobial agents has led to a con-
siderable increase in MDR, XDR, and PDR pathogenic bac-
teria. Colistin has resurfaced as effective last resort for treat-
ment of infections caused by XDR A. baumannii. Many 
studies evaluated the resistance mechanisms against poly-
myxins, and analysed effectiveness of colistin monotherapy 
as well as the combination therapy to reduce the colistin re-
sistance and toxicity of colistin.8,10,25 Despite the efforts, co-
listin therapy-related colistin-resistant A. baumannii strains 
have been isolated.10,26,27 A complete loss of LPS production 
via mutations in LPS-producing genes (lpxA, lpxC, and 
lpxD) and the modification of lipid A components via muta-
tions in the pmrAB gene have been evaluated in various stud-
ies with in vitro manipulated colisitn-resistant A. bauman-
nii.12,13 Between two colistin-resistance mechanisms, only 
mutations in the pmrA (Met12Ile; Met12Lys) or pmrB gene 
(Gln270Pro; Gln277Lys) were found in clinical isolates 
from patient who has been treated with colistin. In our study, 
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